Abstract: Provided are a method for fabricating a highly elastic porous polymer membrane, a method for manufacturing a cell culture system using a porous polymer membrane fabricated by the fabrication method, and a cell culture system manufactured by the manufacturing method. The porous polymer membrane can be fabricated by spin coating a mixture solution containing a biodegradable elastomeric polymer and a water-soluble moisture absorbent in an optimum ratio while maintaining a high relative humidity. The porous polymer membrane has a uniform thickness and a uniform pore size and is highly elastic. In addition, the thickness and pore size of the porous polymer membrane can be controlled. The porous polymer membrane can induce active cell-cell interaction during cell co-culture due to its high porosity. The porous polymer membrane enables control over cell alignment or array due to its high biocompatibility and elasticity.

Abstract: Disclosed are a dynamic random access memory (DRAM) device, an on-die termination (ODT) resistance value setting method thereof, and a computer program therefor, and the DRAM device includes at least one DRAM module and a memory controller configured to measure a resistance value of an ODT resistor corresponding to one of a rank included in the DRAM module, a chipset included in the rank, and a DQ included in the chipset and set a resistance value of an ODT resistor corresponding to one of the rank, the chipset, and the DQ on the basis of the measured resistance value.

Abstract: Disclosed are a dynamic random access memory (DRAM) device, an on-die termination (ODT) resistance value setting method thereof, and a computer program therefor, and the DRAM device includes at least one DRAM module and a memory controller configured to measure a resistance value of an ODT resistor corresponding to one of a rank included in the DRAM module, a chipset included in the rank, and a DQ included in the chipset and set a resistance value of an ODT resistor corresponding to one of the rank, the chipset, and the DQ on the basis of the measured resistance value.

Abstract: Disclosed are a dynamic random access memory (DRAM) device, an on-die termination (ODT) resistance value setting method thereof, and a computer program therefor, and the DRAM device includes at least one DRAM module and a memory controller configured to measure a resistance value of an ODT resistor corresponding to one of a rank included in the DRAM module, a chipset included in the rank, and a DQ included in the chipset and set a resistance value of an ODT resistor corresponding to one of the rank, the chipset, and the DQ on the basis of the measured resistance value.

Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Abstract: A UV-curable hard coating composition and a coated article coated with the coating composition are provided herein. The UV-curable hard coating composition can be coated on a plastic material such as polycarbonate to form a coated film having excellent material adhesion, abrasion resistance, and weather resistance. The coating composition may be coated by a general coating method. In some instances, inorganic particles as a coating component are not included in the coating composition. Few foreign substances are generated during spray-coating using the composition. The coating composition can be easily stored. Also, the coated article can be polished or recoated with the UV-curable hard coating composition if needed.

Abstract: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Abstract: A UV-curable hard coating composition and a coated article coated with the coating composition are provided herein. The UV-curable hard coating composition can be coated on a plastic material such as polycarbonate to form a coated film having excellent material adhesion, abrasion resistance, and weather resistance. The coating composition may be coated by a general coating method. In some instances, inorganic particles as a coating component are not included in the coating composition. Few foreign substances are generated during spray-coating using the composition. The coating composition can be easily stored. Also, the coated article can be polished or recoated with the UV-curable hard coating composition if needed.

Abstract: Disclosed is a polycarbonate article coated with a coating composition for glazing, and in particular, the polycarbonate article coated with the coating composition may have an adhesion property with a material made of polycarbonate, thereby protecting the material made of polycarbonate from ultraviolet rays and the like. In addition, among the coating composition, a primer layer from the coating composition may be applied on the material made of polycarbonate may provide and a hard coating layer painted on the primer layer, thereby providing abrasion resistance. The polycarbonate article of the present invention comprises a polycarbonate panel; a primer layer applied on the panel; and a hard coating layer applied on the primer layer.

Abstract: The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

Abstract: An UV-curable coating composition for a flow coating comprises about 20 to about 35 parts by weight of an aliphatic urethane acrylate oligomer having an unsaturated group; about 15 to about 25 parts by weight of an acrylate monomer having a trifunctional or tetrafuntional unsaturated group; about 1 to about 4 parts by weight of an additive agent including an UV absorbent and a light stabilizer; about 1 to about 3 parts by weight of a photoinitiator; and about 38 to about 55 parts by weight of an alcohol-based or ether-based solvent.

Abstract: The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Abstract: The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

Abstract: The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Abstract: The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

Abstract: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Abstract: The present invention provides a novel amide derivative of formula (I) and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient.